Pancreatic cancer fatalities set to rise
World Health Matters by Gary Finnegan – Italy – Death rates from pancreatic cancer are predicted to increase in men and women in 2014 and beyond, according to… read more.
World Health Matters by Gary Finnegan – Italy – Death rates from pancreatic cancer are predicted to increase in men and women in 2014 and beyond, according to… read more.
University of Utah researcher Eric Garland (pictured) developed a new mindfulness-focused treatment for people with chronic pain that can effectively reduce pain and misuse of opioid painkillers.
New interim analysis study findings presented for the first time today at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans suggest bendamustine and rituximab… read more.
A ground-breaking international collaborative survey, published today in Annals of Oncology, shows that more than half of the world’s population live in countries where regulations that aim to… read more.
by Bruce Sylvester – Researchers report that an experimental cancer drug which has shown efficacy in treating melanoma also shows promise in treating non-small cell lung cancer, a… read more.
Discussion of the abstract by Dr Christopher Lieu, MD, Assistant professor at the University of Colorado. Younger patients with colorectal cancer that has spread (metastasised) to other parts… read more.
Birgitte Pedersen et al, Vejle Hospital, Denmark. Patients with colorectal cancer (CRC) face huge challenges in their everyday lives as a result of their condition and treatments.
Discussion of the abstract by Dr Zoran Gatalica, Adjunct Professor of Pathology at Creighton University School of Medicine .
Report by Esther Drain – Cetuximab resulted in a significant improvement in survival in TP53 WT, high-risk Rectal Cancer.
First ever Europe-wide study reveals that even when undergraduate medical students take a compulsory course on pain, they still only receive on average 12 hours’ training
by Pam Harrison – MSI status has clear prognostic value in stage II CRC Julien Taieb, MD, PhD, University of Paris Descartes, Paris, France Microsatellite instability (MSI), a… read more.
FDA Highlights by Bruce Sylvester – Researchers report from a phase I clinical trial report that diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy have been successfully reprogrammed… read more.